HUGE HEATH BREAKTHROUGH-!
https://www.nbcnews.com/health/heal...rimental-approach-shrank-tumors-one-rcna31437
A woman with pancreatic cancer has been cured for now. T-Cell therapy targeting KRAS G12D.
This is the new breakthrough!
SQZ Bio which we just had the other day as a gummy may play a roll here... I'm looking into it-
I see some applications.
Mirati has had some set backs but are in the game.. Amgen is working on this. Mirati had a so so outcome on their product and MRTX stock crashed last week
31.9% to 39.81.<------
Watch Today) MRTX & SQZ <--------------
Saudi ready to pump more crude to make up for lack of Russia oil. Oil DOWN.>
Ocugen initiated with an Overweight at Cantor Fitzgerald 06:45 OCGN Cantor Fitzgerald analyst…
Piper ups Repare Therapeutics target after 'great deal' with Roche 06:35 RPTX, RHHBY Piper Sandler analyst Joseph Catanzaro raised the firm's price target on Repare Therapeutics (RPTX) to $30 from $25 and keeps an Overweight rating on the shares after the company entered into a license agreement with Roche (RHHBY) for its ATR inhibitor camonsertib. The deal provides Repare
with a $125M upfront payment, the potential of $1.2B in milestones, and the ability to opt-in to 50/50 U.S. co-development and profit share, Catanzaro tells investors in a research note. The analyst views this as a "great deal" for Repare, saying it allows the potential utility to camonsertib to be fully explored, while unloading the development costs, but still having the ability to participate in the longer-term potential upside. Repare now has cash into 2026 and can "aggressively move forward with the rest of its novel and growing precision oncology pipeline," contends the anlayst.
RPTX <-----
OCGN -
RPTX -
UiPath up 7.8% at $18.14 after Q1 earnings beat, FY23 guidance raise 16:51 PATH
Phillips 66 VP Herman sells almost $4.9M in company shares 17:34 PSX Phillips 66 VP Robert Herman disclosed in a filing that he had sold 47,200 shares of company stock at $102.82 per share on May 31, for a total transaction amount of 4,853,279.<-----
THE CHILDREN WILL EAT WELL TONIGHT-!
Chewy reports Q1 Active Customers up 4.2% y/y at 20.6M 16:11 CHWY Reports Q1 Net Sales per Customer $446, up 14.9% y/y.
Chewy jumps 20% to $28.09 after Q1 profit beats estimates 16:38 CHWY <-----
Pure Storage jumps 10% to $26.40 after Q1 results, FY23 guidance beat estimates 16:12 PSTG
Pure Storage raises FY23 revenue view to $2.66B from $2.6B, consensus $2.59B 16:10 PSTG <--------
Oppenheimer upgrades Wolfspeed to Outperform with $105 price target 06:48 WOLF, SEDG As previously reported, Oppenheimer analyst Colin Rusch upgraded Wolfspeed (WOLF) to Outperform from Perform with a $105 price target as he finds it demonstrating a highly defensible technology position poised for outsized growth despite trading at levels with compelling risk/reward profiles. While the analyst expects some inefficiency in Wolfspeed's Mohawk Valley ramp, the company should work through any yield issues in an expedited manner, resulting in steady margin improvement. Rusch also believes Wolfspeed is effectively leveraging SiC wafer and epitaxy capabilities into device wins. This mix shift should increase the revenue potential on current facilities to $2.7B-plus on this footprint, he adds. <----
Blue Apron jumps 19.5% to $3.67 after entering distribution deal on Walmart.com 16:30 APRN
Proterra initiated with a Buy at DA Davidson 16:21 PTRA DA Davidson analyst Michael Shlisky initiated coverage of Proterra with a Buy rating and $10 price target. He views investing in Proterra "like an investment in a subset of pre-vetted, quality EV-truck companies," said Shlisky, who thinks Proterra is emerging as a preferred provider of batteries to electric truck makers.
Desktop Metal management to meet with Benchmark 14:33 DM Meeting to be held in Burlington, MA on June 9 hosted by Benchmark.
BIOTECH
KRAS biotech Mirati delivers so-so news for investors closely watching Amgen battle
By
Annalee ArmstrongMay 7, 2021 12:28pm
